Recent progress in the development of allosteric modulators of mGluR5 - PubMed

Affiliations

• PMID: 17987523

Review

Recent progress in the development of allosteric modulators of mGluR5

Alice L Rodriguez et al. Curr Opin Drug Discov Devel. 2007 Nov.

Abstract

Allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5) have been developed for their therapeutic potential in a variety of disorders including schizophrenia, drug abuse, fragile X syndrome and anxiety. Modulation of the receptor through an allosteric mechanism provides a high degree of selectivity and avoids many of the pitfalls that are associated with direct acting ligands, such as receptor desensitization. Drug discovery activities in this field have advanced rapidly in recent years, with the development of lead compounds often being accelerated through a variety of novel technologies. The promising effects observed for allosteric modulators of mGluR5 in preclinical studies suggest that their continued development may provide therapeutic options for a range of psychiatric and neurological disorders.

Similar articles

• Recent progress in the discovery and development of negative allosteric modulators of mGluR5.

  Lindsley CW, Emmitte KA. Lindsley CW, et al. Curr Opin Drug Discov Devel. 2009 Jul;12(4):446-57. Curr Opin Drug Discov Devel. 2009. PMID: 19562641 Review.

• 3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization.

  Duplantier AJ, Efremov I, Candler J, Doran AC, Ganong AH, Haas JA, Hanks AN, Kraus KG, Lazzaro JT Jr, Lu J, Maklad N, McCarthy SA, O'Sullivan TJ, Rogers BN, Siuciak JA, Spracklin DK, Zhang L. Duplantier AJ, et al. Bioorg Med Chem Lett. 2009 May 1;19(9):2524-9. doi: 10.1016/j.bmcl.2009.03.032. Epub 2009 Mar 14. Bioorg Med Chem Lett. 2009. PMID: 19328692

• Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential.

  Kew JN. Kew JN. Pharmacol Ther. 2004 Dec;104(3):233-44. doi: 10.1016/j.pharmthera.2004.08.010. Pharmacol Ther. 2004. PMID: 15556676 Review.

• A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5.

  O'Brien JA, Lemaire W, Chen TB, Chang RS, Jacobson MA, Ha SN, Lindsley CW, Schaffhauser HJ, Sur C, Pettibone DJ, Conn PJ, Williams DL Jr. O'Brien JA, et al. Mol Pharmacol. 2003 Sep;64(3):731-40. doi: 10.1124/mol.64.3.731. Mol Pharmacol. 2003. PMID: 12920211

• 3-(Imidazolyl methyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers: a novel series of mGluR2 positive allosteric modulators.

  Zhang L, Rogers BN, Duplantier AJ, McHardy SF, Efremov I, Berke H, Qian W, Zhang AQ, Maklad N, Candler J, Doran AC, Lazzaro JT Jr, Ganong AH. Zhang L, et al. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5493-6. doi: 10.1016/j.bmcl.2008.09.026. Epub 2008 Sep 10. Bioorg Med Chem Lett. 2008. PMID: 18812259

Cited by

• Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction.

  Olive MF. Olive MF. Eur J Pharmacol. 2010 Aug 10;639(1-3):47-58. doi: 10.1016/j.ejphar.2010.01.029. Epub 2010 Apr 2. Eur J Pharmacol. 2010. PMID: 20371237 Free PMC article. Review.

• Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.

  Kantrowitz JT, Javitt DC. Kantrowitz JT, et al. Clin Schizophr Relat Psychoses. 2010 Oct;4(3):189-200. doi: 10.3371/CSRP.4.3.6. Clin Schizophr Relat Psychoses. 2010. PMID: 20880830 Free PMC article. Review.

• Fragile X syndrome: an update on developing treatment modalities.

  Healy A, Rush R, Ocain T. Healy A, et al. ACS Chem Neurosci. 2011 Aug 17;2(8):402-10. doi: 10.1021/cn200019z. Epub 2011 Mar 22. ACS Chem Neurosci. 2011. PMID: 22860169 Free PMC article. Review.

• Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.

  Krystal JH, Mathew SJ, D'Souza DC, Garakani A, Gunduz-Bruce H, Charney DS. Krystal JH, et al. CNS Drugs. 2010 Aug;24(8):669-93. doi: 10.2165/11533230-000000000-00000. CNS Drugs. 2010. PMID: 20658799 Review.

• Overview of glutamatergic neurotransmission in the nervous system.

  Niciu MJ, Kelmendi B, Sanacora G. Niciu MJ, et al. Pharmacol Biochem Behav. 2012 Feb;100(4):656-64. doi: 10.1016/j.pbb.2011.08.008. Epub 2011 Aug 26. Pharmacol Biochem Behav. 2012. PMID: 21889952 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database